Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India ○
found
a story from CNBC ⚠️ › World News
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Eli
since
auto-detected in 118 stories
4 days ago
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.
12 days ago
Eli Lilly secures long-awaited FDA approval for its obesity pill. Here's what to know ⊕
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says ⊕
found
Eli Lilly opposes the White House's push to codify "most favored nation" drug pricing into law, CEO Dave Ricks said in an interview with CNBC.
Eli Lilly wins US approval for weight-loss drug in pill form ⊕
found
a story from Financial Times ✅ › Financial Times
New drug Foundayo sets up battle with Novo Nordisk for oral obesity drugs
14 days ago
Eli Lilly to buy Centessa in $6.3 billion deal for sleep medicines ○
Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal valued at about $6.3 billion.
Two Women review – sex comedy remake is French-Canadian answer to Confessions of a Window Cleaner ○
This tale of a pair of women who tire of their partners and arrange sex with strangers is not sexy enough for erotica and not real enough to be drama
Chloé Robichaud’s new film is a remake of the 1970…
15 days ago
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market ○
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the global market.
25 days ago
Eli Lilly's new shot shows solid weight loss in study — plus, a way for Nvidia to perk up ○
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
26 days ago
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial ⊖
Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.
27 days ago
Eli Lilly shares slide after a bearish Wall Street analyst call — here's our view ○
"On balance, we do not like the risk/reward balance in Lilly shares," the analysts wrote.